Can we grow Mycoplasma genitalium from patient samples?

🧪 What was the study about?

Mycoplasma genitalium (MGen) is a type of bacteria that can cause pain when passing urine, increased or unusual vaginal discharge and pelvic pain, and is present in up to a third of people who access sexual health services. Infections are treated with antibiotics, but not all available treatments are effective due to antimicrobial resistance. We can investigate antimicrobial resistance by looking at the genetic material of the bacteria in patient samples, but this approach can’t always predict how the bacteria will respond to certain treatments. Another approach is a technique called antimicrobial susceptibility testing, where bacteria are grown in the lab to test which antibiotics will work. This can provide more detailed information but is known to be challenging, particularly for MGen. This study looked at how practical and successful growing MGen was from patient samples.

❓ Why is this important?

Monitoring antimicrobial resistance in MGen is essential to ensure that people receive the best possible treatments. Understanding resistance helps prevent treatment failures, reduces the spread of MGen, and reduces harms caused by MGen infection.

🔍 What did we do?

We attempted to grow MGen from left-over urine specimens, from men who attended a sexual health service in England. This allowed us to explore the challenges of working with MGen in the lab.

📊 Key findings

· Growing MGen is extremely slow and difficult, making it impractical for routine use in clinics or diagnostic labs.

· We were able to grow one strain of MGen in the lab which will be used to test antibiotics in the future.

💡 What do these findings mean?

Although growing MGen can give valuable information, it takes too long and the success-rate of recovery is too low to make it a practical method to use diagnostically. These findings will inform guidelines about how best to monitor antimicrobial resistance in MGen infections.